mannosebind
lectin
mbl
key
solubl
effector
innat
immun
system
recogn
pathogenspecif
surfac
glycan
surprisingli
lowproduc
mbl
genet
variant
may
predispos
children
immunocompromis
individu
infecti
diseas
common
would
expect
human
popul
sinc
certain
immun
defens
molecul
immunoglobulin
exploit
invas
pathogen
hypothes
mbl
might
also
enhanc
infect
circumst
consequ
low
intermedi
mbl
level
commonli
found
human
popul
might
result
balanc
select
use
model
infect
system
pseudotyp
authent
glycosyl
virus
demonstr
mbl
inde
enhanc
infect
ebola
hendra
nipah
west
nile
virus
low
complement
condit
mechanist
studi
ebola
viru
ebov
glycoprotein
pseudotyp
lentivirus
confirm
mbl
bind
nlink
glycan
epitop
viral
surfac
specif
manner
via
mbl
carbohydr
recognit
domain
necessari
enhanc
infect
mbl
mediat
lipidraftdepend
macropinocytosi
ebov
via
pathway
appear
requir
less
actin
earli
endosom
process
compar
filoviru
canon
endocyt
pathway
use
valid
rna
interfer
screen
identifi
candid
surfac
receptor
mediat
mbldepend
enhanc
ebov
infect
also
identifi
potenti
novel
candid
attach
factor
ebov
find
support
concept
innat
immun
haplotyp
repres
critic
interact
mbl
complement
compon
gene
may
modifi
suscept
resist
certain
glycosyl
pathogen
therefor
higher
level
nativ
exogen
mbl
could
deleteri
set
rel
hypocomplementemia
occur
genet
immunodeplet
activ
infect
find
confirm
hypothesi
pressur
infecti
diseas
may
contribut
part
evolutionari
select
mbl
mutant
haplotyp
citat
brudner
karpel
lear
c
chen
l
yantosca
lm
et
al
lectindepend
enhanc
ebola
viru
infect
via
solubl
transmembran
ctype
lectin
receptor
plo
one
mammalian
virus
coevolv
host
immun
machineri
virus
oblig
intracellular
parasit
outcom
hostviru
interact
rest
delic
balanc
host
defens
damag
caus
virus
addit
virus
develop
counteradapt
strategi
escap
immun
defens
evad
suppress
manipul
host
immun
respons
consequ
favor
genet
trait
host
virus
natur
select
time
human
mannosebind
lectin
mbl
prototyp
solubl
calciumdepend
ctype
lectin
key
first
line
host
defens
molecul
immun
regul
mbl
collabor
network
host
defens
complement
compon
divers
cellular
receptor
ctype
lectin
scaveng
complement
receptor
integrin
tolllik
receptor
tlr
prime
longliv
adapt
immun
mbl
recogn
specif
molecular
pattern
oligosaccharid
includ
dmannos
lfucos
glucos
nacetylglucosamin
decor
surfac
mani
virus
ebola
viru
ebov
hendra
nipah
virus
influenza
virus
sever
acut
respiratori
syndrom
coronaviru
mbl
oligom
form
complex
mblassoci
serin
proteas
masp
dimer
activ
lectin
complement
pathway
enhanc
opsonophagocytosi
pathogen
averag
human
mbl
serum
concentr
mgml
rang
mgml
human
popul
level
ngml
may
associ
increas
suscept
infect
young
children
immunocompromis
individu
interindividu
variabl
mbl
concentr
caus
structur
variant
allel
b
c
exon
gene
disrupt
assembl
mbl
highord
oligom
lead
reduc
mbl
concentr
activ
singl
nucleotid
polymorph
promot
region
hl
xy
untransl
region
pq
regulatori
site
also
modifi
serum
concentr
togeth
sequenc
variat
defin
least
common
human
mbl
haplotyp
dictat
mbl
concentr
complementactiv
capac
mbl
variant
allel
present
approxim
individu
higher
rate
occur
indigen
peopl
africa
south
america
reason
high
rate
sequenc
variat
unresolv
controversi
postul
highproduc
ancestr
haplotyp
allel
evolv
multipl
low
mblproduc
haplotyp
heterot
balanc
select
individu
carri
structur
regulatori
heterozyg
polymorph
surviv
advantag
known
whether
viral
infect
exert
select
pressur
time
ebov
nonseg
negativestrand
rna
viru
order
mononegaviral
famili
filovirida
caus
rapidli
fatal
viral
hemorrhag
fever
part
dysregul
innat
immun
system
highli
glycosyl
viral
envelop
glycoprotein
gp
mediat
receptor
bind
gp
virushost
cell
membran
fusion
gp
target
ubiquit
lectin
molecul
express
macrophag
dendrit
cell
endotheli
cell
previous
demonstr
recombin
human
mbl
rhmbl
bind
ebov
gp
refer
gp
lentivir
virionlik
particl
wildtypelik
ebov
specif
dosedepend
manner
treatment
mice
infect
nativ
ebov
use
supraphysiolog
dosag
rhmbl
protect
effect
requir
intact
complement
compon
function
taken
togeth
data
suggest
mbl
lectin
complement
pathway
influenc
cours
ebov
infect
virus
infect
cell
coopt
exist
cellular
structur
function
respons
endocytosi
fluid
small
particl
cellcel
recognit
ion
transport
bind
extracellular
matrix
first
virus
bind
attach
factor
cognat
receptor
help
concentr
viru
cell
surfac
upon
bind
receptor
promot
endocytosi
trigger
direct
fusion
viral
host
cellmembran
ebov
intern
primarili
macropinocytosi
wherea
certain
virus
enter
cell
via
clathrinco
pit
caveolarlipidraft
structur
caveolinraftindepend
mechan
gener
specif
receptor
bind
determin
cell
tropism
type
receptor
engag
viru
determin
choic
endocyt
pathway
notabl
ebov
broad
cell
tropism
especi
later
cours
infect
may
bind
multipl
attach
factor
notabl
among
numer
lectin
dcsignlsign
mgl
lsectin
niemannpick
endosom
membran
protein
addit
famili
member
axl
dtk
mer
integrin
wide
express
implic
ebolagp
mediat
cell
entri
tcell
immunoglobulin
mucin
domain
recent
propos
epitheli
receptor
bind
ebov
gp
receptor
bind
region
cognat
receptor
monocyt
macrophag
dendrit
cell
yet
identifi
varieti
virus
includ
ebov
dengu
virus
west
nile
viru
wnv
coxsacki
b
viru
ross
river
viru
exploit
antibodi
activ
complement
compon
enhanc
entri
target
cell
process
call
antibodydepend
enhanc
ade
start
crosslink
virusantibodi
virusantibodycompl
complex
fcc
complement
receptor
respect
viru
may
coupl
cognat
receptor
cell
surfac
therebi
facilit
entri
noteworthi
viral
specif
antibodi
either
neutral
enhanc
product
ebov
wnv
infect
depend
antibodi
concentr
class
complement
compon
concentr
type
cell
densiti
epitop
effector
mechan
mediat
crystalliz
fragment
fc
antibodi
also
postul
rapid
spread
ebov
secondari
target
cell
eg
hepatocyt
endotheli
cell
occur
mean
ade
via
wide
distribut
receptor
mbl
describ
anteantibodi
repres
primit
nonclon
form
humor
immun
evolutionarili
predat
antibodi
analog
antibodi
mbl
mediat
opsonophagocytosi
bind
cellular
receptor
via
collagen
tail
addit
mbl
structur
function
homolog
bind
cognat
cellular
receptor
andor
activ
complement
pathway
via
action
serin
proteas
given
function
similar
mbl
either
antibodi
consid
novel
mbl
receptormedi
mechan
enhanc
infect
ebov
virus
whose
virion
highli
glycosyl
might
explain
heterot
balanc
select
may
contribut
evolutionari
diverg
human
mbl
haplotyp
given
propos
model
lectin
might
enhanc
ebov
infect
investig
possibl
human
mbl
could
enhanc
infect
human
cell
ebov
gppseudotyp
lentivirus
wildtypelik
ebov
glycosyl
virion
low
complement
condit
initi
confirm
model
pursu
mechanist
studi
dynam
mblmediat
endocytosi
identifi
candid
mbl
viral
receptor
use
rna
interfer
rnai
approach
obtain
written
inform
consent
elig
healthi
adult
volunt
blood
sampl
accord
protocol
approv
massachusett
gener
hospit
institut
review
board
reagent
purchas
sigmaaldrich
st
loui
mo
except
list
jasplakinolid
purchas
emd
bioscienc
san
diego
ca
latrunculin
b
enzo
life
scienc
intern
plymouth
meet
pa
wildtypelik
cyanovirinn
mutant
kindli
donat
e
matei
rhmbl
provid
enzon
pharmaceut
bridgewat
nj
notabl
rhmbl
similar
structur
function
nativ
human
mbl
form
predominantli
high
molecular
mass
multim
kda
complement
compon
serum
purchas
quidel
san
diego
ca
recombin
human
purchas
r
system
minneapoli
mn
nglycosidas
f
pngase
f
endoglycosidas
h
new
england
biolab
ipswich
antihmbl
antibodi
hyb
bioporto
gentoft
denmark
use
mannanbind
complement
compon
cleavag
assay
antihuman
mbl
neutral
monoclon
antibodi
produc
gl
stahl
isotyp
control
obtain
beckman
coulter
hebron
ky
puromycin
alamarblu
cell
viabil
reagent
resazurin
invitrogen
carlsbad
ca
thermolysin
sigmaaldrich
deriv
thermoproteolyticu
rokko
biotinyl
hippeastrum
hybrid
amarylli
lectin
obtain
vector
laboratori
burlingam
ca
cell
line
purchas
american
type
cultur
collect
atcc
manassa
va
maintain
humidifi
incub
co
follow
media
vero
cell
eagl
minimum
essenti
medium
emem
cell
dulbecco
modifi
eagl
medium
dmem
hepe
hek
nacetylglucosaminyltransferas
gnti
cell
dmem
cell
peripher
blood
mononuclear
cell
pbmc
media
supplement
fetal
bovin
serum
invitrogen
uml
penicillin
mgml
streptomycin
note
cell
adher
tissu
cultur
micropl
corn
incub
fbssupplement
media
pbmc
isol
fresh
singledonor
buffi
coat
sampl
massachusett
gener
hospit
mgh
blood
bank
use
vacutain
cpt
cell
prepar
tube
sodium
citrat
bd
franklin
lake
nj
accord
manufactur
instruct
cell
seed
fb
cm
tissuecultur
dish
hour
nonadher
cell
remov
wash
twice
adher
pbmc
detach
cell
scraper
seed
well
tissuecultur
plate
fb
ngml
mcsf
induc
differenti
monocytederiv
macrophag
day
cell
incub
fresh
media
ml
mcsf
ngml
ad
day
cell
infect
day
assay
infect
day
mannanbind
cleavag
assay
perform
describ
elsewher
isol
genom
dna
ml
whole
blood
obtain
ethnic
divers
consent
healthi
volunt
accord
manufactur
instruct
gentra
puregen
blood
kit
qiagen
valencia
ca
primer
pcr
reaction
condit
genotyp
adapt
steffensen
et
al
modif
protocol
describ
method
pseudotyp
virus
hivebov
gp
hivebovdgp
amino
acid
delet
mucinrich
region
downstream
ebov
bind
region
hivvesicular
stomat
viru
vsv
g
hivenvelop
env
neg
virion
encod
firefli
luciferas
produc
describ
elsewher
use
pseudotyp
viral
construct
pseudotyp
virionlik
particl
concentr
determin
elisa
quantit
core
protein
accord
manufactur
instruct
allianc
perkinelm
waltham
wild
type
wildtypelik
virus
wildtypelik
recombin
ebov
mayinga
variant
egfp
genbank
access
number
hendra
nipah
virus
prepar
laboratori
quantifi
spectrofluoromet
immunoassay
respect
describ
elsewher
detail
hendra
nipah
viru
variant
report
elsewher
wnv
replicon
plasmid
pwiirepgfp
kindli
provid
dr
dom
univers
pennsylvania
school
medicin
code
region
wnv
strain
capsid
c
premembran
prm
envelop
e
protein
clone
pcaggsmc
vector
glycosyl
mutant
wnv
e
protein
introduc
use
quikchang
method
invitrogen
west
nile
virionlik
particl
produc
previous
report
describ
method
infect
perform
white
clear
bottom
cell
cultur
micropl
unless
indic
otherwis
pseudotyp
virion
singleround
infect
assay
adher
gnti
cell
ml
incub
emem
fb
respect
hour
confluent
approxim
ml
cell
ml
stimul
pma
ngml
supplement
ngml
upregul
potenti
ebov
receptor
becam
differenti
adher
hour
incub
rpmi
fb
monocytederiv
macrophag
prepar
maintain
describ
inoculum
consist
pg
ml
viral
construct
unless
indic
otherwis
pg
hiv
correspond
approxim
hiveboz
gp
virionlik
particl
accord
formula
mass
molmw
gmol
mol
molecul
base
calcul
estim
virionlik
particl
cell
ratio
approxim
moi
cell
cell
infect
cell
sera
virionlik
particl
andor
cell
prepar
follow
mblreplet
defici
lypblypb
mbl
ngml
sera
preincub
dilut
oligosaccharid
mannan
polyethylen
glycol
edta
isotyp
control
minut
virionlik
particl
preincub
dilut
human
sera
pretreat
certain
experi
rhmbl
cyanovirinn
pngase
f
endo
h
thermolysin
serumfre
media
hour
cell
preincub
dilut
pharmacolog
inhibitor
endocytosi
hour
nglycosyl
inhibitor
hour
appropri
control
dimethyl
sulfoxid
dmso
methanol
endocytosi
inhibitor
reagent
dilut
dmem
veronalbuff
salin
vb
barbit
mm
sodium
barbit
mm
nacl
achiev
optim
rate
infect
final
cacl
concentr
mm
unless
indic
otherwis
media
remov
cell
except
media
contain
pharmacolog
inhibitor
endocytosi
inoculum
prepar
ad
note
cell
preincub
methylbcyclodextrin
wash
twice
phosphatebuff
salin
pb
viru
ad
obviat
disrupt
virion
glycan
envelop
micropl
centrifug
hour
room
temperatur
spinocul
step
incub
co
hour
thereaft
inoculum
prepar
replac
fresh
media
contain
fb
incub
co
hour
cell
viabil
assess
alamarblu
reagent
resazurin
reduct
assay
measur
fluoresc
hour
nm
excit
nm
emiss
certain
experi
use
variou
virionlik
particl
eg
hivebov
hivvsvg
hivenv
neg
hivebov
dgp
potenti
toxic
chemic
eg
edta
nglycosyl
inhibitor
may
differenti
impair
cell
prolifer
cell
lyse
singl
round
infect
cell
quantifi
detect
chemiluminesc
measur
luciferas
assay
accord
manufactur
instruct
promega
madison
wi
fluoresc
luminesc
read
spectramax
micropl
reader
molecular
devic
sunnyval
ca
luciferas
valu
express
rel
light
unit
per
second
rlusec
adjust
cell
viabil
appropri
adjust
luciferas
valu
defin
luciferas
rlusec
alamarblu
fluoresc
unit
experi
perform
twice
quadrupl
wild
typelik
recombin
ebov
mayinga
variant
egfp
viru
modifi
previous
describ
infect
assay
briefli
virion
preincub
media
mbldefici
serum
ngml
without
mgml
mbl
final
concentr
hour
virion
prepar
ad
ml
cell
multipl
infect
hour
certain
experi
mbl
preincub
mannan
cell
preincub
tunicamycin
describ
thereaft
viral
inoculum
replac
fresh
dmem
incub
hour
fluoresc
read
spectrofluoromet
molecular
devic
excit
nm
emiss
nm
experi
perform
twice
triplic
hendra
viru
nipah
viru
infect
assay
describ
detail
elsewher
follow
modif
virus
tcid
ml
preincub
heatinactiv
mbldefici
serum
ngml
without
mgml
rhmbl
minut
ad
inoculum
vero
cell
hour
experi
perform
twice
duplic
west
nile
viru
cellswel
plate
tissuecultur
plate
ml
dmem
fb
hour
ml
west
nile
virionlik
particl
preincub
ml
dmem
mbldefici
human
serum
without
mgml
rhmbl
hour
cell
cultur
medium
replac
ml
west
nile
virionlik
particl
prepar
plate
spinocul
hour
virionlik
particl
prepar
replac
mlwell
dmem
fb
incub
hour
cell
detach
use
trypl
invitrogen
wash
three
time
pb
cell
resuspend
ml
pb
rate
transduct
assay
flow
cytometri
experi
perform
twice
triplic
variou
concentr
fitcdextran
preincub
dilut
rhmbl
fb
minut
fitcdextran
without
mbl
incub
pmastimul
supplement
cell
ml
reaction
volum
dark
hour
effect
mbl
fitcdextran
endocytosi
gfp
express
west
nile
virionlik
particletransduc
cell
analyz
flow
cytometri
data
acquir
use
facscalibur
flow
cytomet
bd
bioscienc
san
jose
ca
analyz
use
cellquest
pro
softwar
bd
bioscienc
percentag
mean
fluoresc
intens
mfi
gfpexpress
cell
within
live
cell
popul
determin
analyz
function
product
percentag
mfi
experi
perform
twice
triplic
infect
perform
rnai
lossoffunct
screen
hightit
lentivir
vector
carri
puromycinresist
gene
drive
short
hairpin
rna
shrna
express
human
promot
identifi
potenti
receptor
attach
factor
ebov
andor
mblmediat
viral
uptak
obtain
uniqu
shrna
construct
per
gene
rnai
consortium
broad
institut
massachusett
institut
technolog
target
candid
lectin
scaveng
human
receptor
receptorlik
molecul
tabl
cathepsinl
implic
ebov
pathogenesi
eg
dcsign
mgl
lsectin
well
empti
vector
cultiv
cell
ml
micropl
emem
fb
co
hour
confluenc
adher
cell
transduc
quadrupl
incub
shrna
virus
control
vector
particl
hexadimethrin
bromid
mgml
cell
hour
medium
replac
fresh
complet
medium
contain
mgml
puromycin
optim
concentr
determin
preliminari
kill
curv
experi
incub
hour
time
cell
viabil
assay
alamarblu
reagent
accord
manufactur
instruct
hivebovgp
infect
singl
round
preincub
pseudotyp
ebov
virionlik
particl
pg
ml
without
mbl
mgml
vb
hour
use
virionlik
particl
infect
quadrupl
shrnainfect
cell
maintain
mgml
puromycin
hour
measur
luciferas
express
describ
infect
assay
adjust
result
cell
viabil
calcul
percentag
chang
luciferas
activ
caus
shrna
rel
empti
control
vector
posit
hit
defin
reduct
infect
least
two
shrna
construct
particular
gene
cultiv
cell
well
dmem
fb
format
hour
transduc
cell
shrna
virus
identifi
hit
rnai
screen
well
nontarget
shrnagfp
control
mgml
hexadimethrin
bromid
hour
replac
inoculum
prepar
fresh
complet
media
contain
mg
ml
puromycin
harvest
cell
least
hour
cellular
lysat
extract
shrnatreat
cell
qiagen
allprep
protein
kit
protein
concentr
measur
use
nanodrop
spectrophotomet
mg
lysat
mix
laemmli
load
buffer
dtt
mm
final
concentr
fraction
gradient
minigel
biorad
transfer
nitrocellulos
membran
protein
molecular
weight
determin
use
invitrogen
novex
prestain
protein
standard
membran
block
bsa
dissolv
pbst
solut
mm
nacl
mm
kcl
mm
phosphat
buffer
ph
hour
follow
incub
primari
antibodi
overnight
dilut
select
antibodi
follow
santa
cruz
abcam
biovis
novu
biolog
actin
millipor
membran
triplewash
pbst
minut
incub
appropri
secondari
antibodi
goat
antirabbit
igghrp
goat
antimous
igghrp
santa
cruz
pbst
minut
tripl
wash
ecl
reagent
appli
membran
visual
autoradiographi
mrna
express
candid
gene
measur
quantit
realtim
pcr
describ
detail
see
method
tabl
normal
distribut
data
compar
analysi
varianc
test
skew
data
analyz
mannwhitney
u
kruskalw
test
categor
data
compar
student
tor
fisher
exact
test
appropri
tukey
test
use
allpairwis
multipl
comparison
procedur
data
figur
shown
mean
standard
error
mean
test
twotail
p
valu
consid
statist
signific
mannosebind
lectin
key
host
defens
molecul
collabor
complement
solubl
cellderiv
molecul
limit
invas
pathogen
previous
demonstr
rhmbl
effect
inhibit
infect
human
cell
ebov
gppseudotyp
lentivir
virion
wild
typelik
ebov
presenc
activ
complement
serum
cours
experi
surpris
confirm
complement
essenti
inhibitori
effect
rhmbl
absenc
found
preliminari
evid
suggest
paradox
rhmbldepend
increas
ebov
infect
varieti
human
cell
line
includ
cell
produc
highli
reproduc
result
potenti
bind
ebov
receptor
bind
region
greater
extent
cell
given
wealth
exampl
virus
subvert
immun
defens
molecul
viru
entri
given
evid
select
pressur
highproduc
mbl
haplotyp
human
popul
sought
defin
mechan
mbl
might
enhanc
infect
human
cell
ebov
also
evalu
effect
mbl
infect
glycosyl
virus
low
complement
state
determin
whether
mechan
relev
glycosyl
virus
gener
first
found
hivebov
gp
virionlik
particl
infect
cell
greater
extent
presenc
mbl
absenc
rhmbl
enhanc
infect
dosedepend
manner
either
absenc
serum
figur
rel
low
concentr
mbldefici
serum
figur
experi
mbl
maxim
enhanc
viral
infect
approxim
rhmbldepend
enhanc
hivebov
gp
infect
requir
ebov
glycoprotein
sinc
rhmbl
enhanc
infect
hivenv
neg
hivvsvg
figur
permiss
effect
rhmbl
calciumdepend
expect
ctype
lectin
figur
determin
whether
nativ
hmbl
could
also
enhanc
ebov
infect
collect
panel
human
sera
mbl
concentr
cleavag
activ
span
normal
rang
mbl
variat
human
popul
figur
test
rel
effect
sera
three
individu
undetect
intermedi
high
mbl
level
degre
hivebov
gp
infect
cell
degre
infect
strongli
associ
nativ
mbl
level
serum
concentr
figur
importantli
ebov
infect
inhibit
serum
concentr
presenc
higher
mbl
concentr
figur
report
previous
valid
associ
demonstr
strong
correl
infect
mbl
level
use
serum
panel
human
sera
mbl
concentr
curv
r
mbl
cleavag
activ
curv
r
figur
find
substanti
hypothesi
nativ
mbl
play
signific
role
enhanc
ebov
infect
given
mbl
activ
lectin
complement
pathway
requir
block
ebov
infect
question
effect
inactiv
complement
would
mbl
capac
enhanc
viral
infect
mbl
form
complex
mblassoci
serin
proteas
masp
upon
bind
pathogen
mblmasp
sequenti
cleav
complement
compon
catalyt
product
complement
compon
form
complex
act
convertas
key
enzym
lectin
complement
pathway
cleavag
process
convertas
produc
sever
compon
eg
potent
activ
immun
system
bind
complement
receptor
lead
enhanc
phagocytosi
profession
phagocyt
increas
cytotox
nk
cell
base
fact
complement
heat
labil
show
heat
inactiv
serum
revers
inhibitori
effect
viral
infect
higher
serum
concentr
contain
higher
nativ
mbl
level
albeit
vari
extent
figur
defin
critic
contribut
complement
compar
effect
human
sera
remov
immun
precipit
contain
lack
nativ
mbl
figur
notabl
mblreplet
serum
enhanc
infect
maxim
dilut
mbl
concentr
greatest
effect
could
revers
supplement
perform
twice
quadrupl
preincub
hivebovgp
virionlik
particl
serum
ethnic
divers
individu
shown
associ
level
infect
nativ
mbl
activ
mannanbind
cleavag
individu
r
serum
cleavag
activ
r
serum
mblmannan
bind
experi
perform
quadrupl
e
preincub
hivebovgp
virionlik
particl
heatinactiv
serum
minut
three
individu
vari
mbl
level
infect
cell
f
preincub
hivebov
gp
virionlik
particl
media
sera
dilut
complement
compon
replet
deplet
lack
contain
approxim
equival
mbl
concentr
ngml
addit
deplet
serum
reconstitut
recombin
human
mgml
comparison
experi
perform
twice
quadrupl
recombin
human
complementreplet
serum
without
nativ
mbl
augment
infect
figur
mannosebind
lectin
recogn
specif
configur
hexos
sugar
includ
dmannos
glucos
lfucos
nacetylglucosamin
galactos
sialic
acid
ascertain
whether
mbl
mediat
viral
infect
via
lectin
carbohydr
recognit
domain
preincub
human
serum
mbl
concentr
ngml
competitor
carbohydr
dmannos
nacetylglucosamin
figur
mannan
polym
mannos
figur
reduc
hivebov
gp
infect
wherea
inhibitori
effect
galactos
nacetylgalactosamin
figur
polydispers
polyethylen
glycol
figur
significantli
less
absent
edta
also
reduc
infect
consist
mbl
carbohydr
recognit
domain
depend
calcium
bind
figur
relat
experi
antimbl
neutral
monoclon
antibodi
inhibit
hivebov
gp
infect
figur
investig
potenti
viral
epitop
target
mbl
use
cyanovirinn
cvn
cyanobacteri
lectin
bind
high
specif
affin
epitop
termin
end
nlink
highmannos
oligosaccharid
cvn
inhibit
rhmblmediat
enhanc
hivebov
gp
infect
dosedepend
manner
ic
nm
indic
lectin
either
share
viral
epitop
compet
via
steric
hindranc
figur
explor
whether
nlink
glycan
viral
gp
requir
mblmediat
uptak
deglycosyl
hivebov
gp
virionlik
particl
ad
rhmbl
compar
effect
two
endoglycosidas
pngase
f
endo
h
predict
cleav
nlink
glycan
differ
site
unlik
pngase
f
endo
h
leav
singl
glcnac
residu
potenti
bind
site
mbl
figur
b
first
confirm
endoglycosidas
fact
remov
highmannos
moieti
gp
endoglycosidasetr
hivebov
virus
prove
western
blot
use
biotinyl
hippeastrum
hybrid
amarylli
lectin
detect
amannos
residu
hybrid
lectin
bind
aglucosyl
structur
highmannos
present
substanti
quantiti
untreat
nondeglycosyl
viru
figur
found
pngase
f
inhibit
infect
dosedepend
manner
presenc
rhmbl
figur
wherea
heatinactiv
pngase
f
inhibit
infect
figur
contrast
effect
neither
activ
heatinactiv
endo
h
inhibit
infect
figur
test
mbl
effect
hivebovdgp
lack
portion
glycosyl
mucinrich
region
thought
import
viral
pathogenesi
mbl
exhibit
reduc
capac
enhanc
infect
hivebovdgp
compar
hivebov
express
wild
type
gp
figur
confirm
find
preincub
hivebov
gp
virionlik
particl
thermolysin
bacteri
metalloproteas
cleav
mucin
region
glycan
cap
ebov
gp
support
hypothesi
mbl
bind
glycanrich
region
demonstr
thermolysin
abrog
mblmediat
enhanc
hivebov
gp
infect
thermolysinconcentr
depend
manner
presenc
rhmbl
maxim
reduct
viral
infect
wherea
inhibit
infect
absenc
mbl
figur
final
investig
whether
glycoprotein
nlink
glycan
cell
surfac
requir
mblmediat
uptak
demonstr
mblmediat
infect
almost
complet
abrog
tunicamycin
chemic
inhibitor
nacetylglucosaminyltransferas
gnti
initi
glycosyl
process
cellular
glycoprotein
figur
preincub
cell
swainsonin
block
carbohydr
trim
inhibit
glucosidas
iii
amannosidas
ii
also
reduc
mblmediat
infect
albeit
lesser
extent
tunicamycin
rel
control
mbl
enhanc
viral
uptak
figur
chemic
inhibitor
potenti
cytotox
account
differ
cell
viabil
mean
cell
prolifer
assay
alamarblu
resazurin
reduct
assay
similarli
mblmediat
enhanc
infect
seen
cell
genet
defici
nacetylglucosaminyltransferas
figur
mbl
mediat
ebov
infect
via
canon
macropinocytosislik
pathway
distinct
endocyt
traffick
may
defin
novel
uptak
mechan
canon
ebov
viral
entri
util
cholesterolrich
lipid
raftdepend
macropinocytosislik
pathway
test
sever
pharmacolog
perturb
endocytosi
investig
whether
mbl
enhanc
viral
uptak
via
canon
pathway
mediat
altern
traffick
amilorid
analog
eipa
import
macropinosom
format
inhibit
infect
cell
presenc
absenc
rhmbl
indic
macropinocytosi
primari
mechan
entri
figur
amilorid
hydrochlorid
also
inhibit
macropinocytosi
produc
similar
result
figur
absenc
differenti
effect
methylbcyclodextrin
likewis
suggest
lipid
raft
requir
viral
infect
regardless
presenc
mbl
figur
final
viral
infect
depend
microtubul
function
without
mbl
importantli
mbl
reduc
depend
function
actin
figur
confirm
earli
endosom
acidif
import
ebov
infect
evidenc
fact
lysosomotrop
agent
bafilomycin
specif
potent
inhibitor
vacuolar
h
atpas
earli
endosom
reduc
infect
significantli
lesser
extent
presenc
mbl
suggest
mblmediat
endocytosi
bypass
earli
endosom
figur
hand
monensin
carboxyl
ionophor
inhibit
endosom
acidif
receptor
recycl
attenu
infect
similar
extent
presenc
absenc
mbl
figur
agreement
saeed
et
al
use
replicationcompet
infecti
ebov
found
dynasor
potent
specif
dynamin
inhibitor
signific
effect
infect
regardless
presenc
mbl
figur
suggest
vesicl
bud
common
clathrinand
caveolinmedi
endocytosi
contribut
viral
entri
cell
final
test
whether
mbl
role
mediat
endocytosi
target
specif
found
physiolog
concentr
mbl
bound
effect
dextran
prototyp
fluid
phase
marker
macropinocytosi
figur
howev
mbl
enhanc
uptak
dextran
figur
therefor
conclud
mbl
enhanc
ebov
infect
targetspecif
manner
determin
whether
mbl
enhanc
viral
uptak
ebov
prototyp
target
cell
monocyt
macrophag
test
whether
mbl
enhanc
hivebov
gp
infect
activ
cell
human
monocyt
cell
line
primari
human
macrophag
found
rhmbl
enhanc
infect
cell
type
low
complement
condit
figur
separ
experi
infect
cell
significantli
inhibit
preincub
serum
nativ
mbl
concentr
ngml
competitor
edta
reduct
mm
figur
mannan
reduct
mgml
figur
reduct
mgml
figur
furthermor
mbl
capac
enhanc
infect
significantli
reduc
ebov
gp
mucinrich
region
mutat
figur
sought
identifi
candid
receptor
might
involv
mblenhanc
ebov
infect
use
short
hairpin
sh
rnaexpress
lentivir
construct
knock
express
candid
lectin
scaveng
human
cellular
receptor
tabl
cell
infect
cell
hivebov
gp
quadrupl
presenc
absenc
rhmbl
first
instanc
five
differ
shrna
target
endosom
proteas
figur
reduc
infect
presenc
absenc
mbl
lent
credenc
valid
assay
proteolysi
figur
mbl
interact
hivebov
gp
via
mbl
carbohydr
recognit
domain
preincub
serum
contain
nativ
human
mbl
ngml
mm
hexos
monosaccharid
edta
dilut
media
b
mgml
mannan
polydispers
polyethylen
glycol
peg
room
temperatur
minut
incub
serum
hivebov
gp
pg
ml
hour
infect
adher
cell
luciferas
valu
adjust
cell
viabil
use
alamarblu
resazurin
reduct
assay
observ
rel
toxic
associ
mm
edta
invalid
result
adjust
cell
viabil
c
repeat
previou
experi
antihuman
mbl
monoclon
antibodi
isotyp
control
preincub
minut
signific
differ
shown
preincub
hivebov
gp
virionlik
particl
cyanovirin
nm
hour
incub
particl
serum
presenc
absenc
rhmbl
luciferas
valu
adjust
cell
viabil
experi
perform
twice
quadrupl
b
nglycosidas
f
pngase
f
amidas
cleav
linkag
innermost
glcnac
asparagin
residu
within
highmannos
hybrid
complex
oligosaccharid
nlink
glycoprotein
therebi
produc
carbohydratefre
peptid
without
potenti
ligand
mbl
endoglycosidas
h
endo
h
cleav
linkag
within
diacetylchitobios
stem
highmannos
nlink
glycoprotein
therebi
gener
truncat
sugar
molecul
one
nacetylglucosamin
residu
potenti
target
mbl
remain
asparagin
man
mannos
glcnac
nacetylglucosamin
asn
asparagin
variou
oligosaccharid
n
residu
preincub
hivebovgp
virionlik
particl
pg
ml
hour
c
pngase
f
endo
h
uml
concentr
heat
inactiv
enzym
incub
virus
mbldefici
serum
presenc
absenc
rhmbl
hour
infect
cell
signific
differ
shown
e
preincub
cell
hour
chemic
tunicamycin
swainsonin
deoxynojirimycin
inhibit
variou
stage
nlink
glycosyl
infect
cell
hivebovgp
virionlik
particl
pg
ml
preincub
mbldefici
serum
supplement
variou
concentr
rhmbl
signific
differ
shown
pairwis
comparison
mgml
rhmbl
respect
f
cultiv
defici
nacetylglucosaminyltransferas
cell
mbldefici
serum
supplement
variou
concentr
rhmbl
infect
cell
hivebovgp
virionlik
particl
pg
ml
absenc
presenc
mgml
tunicamycin
statist
differ
among
inhibitor
variou
rhmbl
concentr
shown
pairwis
comparison
mgml
rhmbl
respect
luciferas
valu
adjust
cell
viabil
use
alamarblu
resazurin
reduct
assay
experi
perform
twice
quadrupl
ebov
gp
cathepsinl
host
cell
endosom
critic
step
viral
entri
rnai
consortium
broad
institut
previous
valid
specif
five
cathepsinl
shrna
gene
transcript
assay
silver
person
commun
perform
western
blot
valid
reduc
protein
express
proceed
demonstr
knockdown
mgl
reduc
infect
figur
verifi
knockdown
mgl
gene
express
measur
mrna
transcript
rel
nontarget
shrna
control
demonstr
variabl
reduct
mgl
shrna
construct
respect
figur
method
howev
hand
signific
differ
protein
express
compar
empti
control
vector
data
shown
also
found
reduct
infect
cell
treat
one
shrna
reduc
gene
express
reduc
protein
express
data
shown
find
conclus
conflict
role
protein
report
other
play
ebov
pathogenesi
screen
select
candid
attach
factor
tabl
demonstr
shrnamedi
knockdown
dendrit
cellassoci
ctype
lectin
reduc
hivebov
gp
infect
regardless
presenc
mbl
figur
knockdown
reduc
hivebov
gp
infect
significantli
greater
extent
presenc
rhmbl
absenc
one
shrna
construct
figur
shrna
construct
therebi
potenti
identifi
novel
mblmediat
viral
uptak
pathway
knockdown
protein
express
confirm
western
blot
singl
clear
band
detect
figur
figur
adjust
variat
protein
load
rel
actin
control
confirm
protein
express
reduc
four
shrna
figur
reduc
three
shrna
figur
compar
empti
control
vector
experi
valid
find
infect
assay
also
show
mean
quantit
realtim
pcr
gene
transcript
knock
four
shrna
final
confirm
mblenhanc
viral
infect
relev
nativ
viral
infect
test
wild
typelik
ebov
rhmbl
enhanc
ebov
infect
low
complement
condit
figur
seen
pseudotyp
virus
mbldepend
enhanc
infect
block
preincub
rhmbl
mannan
figur
pretreat
cell
tunicamycin
dosedepend
manner
figur
evalu
generaliz
observ
glycosyl
virus
test
three
addit
nativ
viral
infect
model
rhmbl
enhanc
nativ
nipah
hendra
viral
infect
hypocomplementem
condit
respect
figur
addit
rhmbl
significantli
enhanc
west
nile
virionlik
particl
transduct
low
complement
condit
effect
glycosylationdefici
wnv
mutant
strain
figur
mannosebind
lectin
multifunct
pattern
recognit
receptor
play
key
role
finetun
innat
immun
system
sinc
mbl
defici
first
discov
caus
common
opson
defect
children
better
understand
divers
function
evolv
mbl
bind
invari
glycan
divers
microorgan
includ
ebov
upregul
opsonophagocytosi
activ
lectin
complement
pathway
amplifi
host
respons
cooper
differenti
regul
cytokin
product
yet
cogent
explan
evolutionari
select
lowproduc
mbl
haplotyp
particularli
indigen
african
south
american
lack
describ
first
time
mbl
enhanc
ebov
wnv
infect
lesser
extent
hendra
nipah
virus
low
complement
condit
find
suggest
certain
infecti
diseas
may
neg
select
highproduc
mbl
genotyp
provid
new
insight
ebov
pathogenesi
accord
current
accept
paradigm
mbl
defici
predispos
children
immunocompromis
individu
invas
diseas
wherea
normal
high
level
mbl
protect
contrast
demonstr
appar
paradox
phenomenon
recombin
human
mbl
nativ
mbl
panel
human
serum
sampl
enhanc
pseudotyp
wild
typelik
ebov
infect
human
cell
complement
compon
reduc
remov
figur
heat
inactiv
serum
similar
albeit
diminish
effect
heat
also
reduc
cleavag
activ
mbl
data
shown
demonstr
mbl
bind
ebov
via
highli
specif
interact
mbl
carbohydr
recognit
domain
process
calciumdepend
would
expect
c
type
lectin
figur
show
high
affin
mbl
ligand
eg
dmannos
compet
viralbind
mbl
figur
b
neutral
monoclon
antibodi
bind
hing
region
within
mbl
carbohydr
recognit
domain
block
enhanc
infect
figur
sought
identifi
specif
residu
viral
surfac
target
mbl
base
repertoir
mbl
typic
ligand
hypothes
target
glycoprotein
critic
viru
stabil
cell
tropism
immun
evas
host
cell
invas
ebov
virus
hendra
nipah
virus
wnv
hepat
c
viru
influenza
virus
metapneumovirus
sarscorona
viru
use
host
cell
machineri
modifi
viral
surfac
protein
nlink
glycosyl
process
involv
attach
highmannos
core
amid
nitrogen
asparagin
follow
trim
remodel
viral
oligosaccharid
endoplasm
reticulum
golgi
apparatu
ebov
gp
heavili
glycosyl
nand
olink
glycan
constitut
onethird
molecular
mass
major
nlink
glycan
concentr
glycan
cap
mucinlik
region
reminisc
glycan
shield
hiv
epsteinbarr
viru
investig
specul
glycan
may
help
ebov
evad
immun
respons
mask
put
ebov
receptorbind
region
viral
glycan
may
also
recogn
ctype
lectin
receptor
either
membraneassoci
eg
dcsign
solubl
eg
mbl
sever
virus
hijack
type
molecul
enter
cell
propag
establish
mbl
bind
nlink
glycan
viral
surfac
show
cyanovirinn
lectin
target
nlink
highmannos
great
specif
affin
compet
preincub
nativ
hendra
nipah
virus
tcid
ml
heatinactiv
mbldefici
serum
without
rhmbl
infect
vero
cell
hour
hour
infect
detect
chemiluminescencebas
viral
protein
immunoassay
comparison
baselin
valu
p
p
c
preincub
ml
west
nile
virionlik
particlegfp
media
alon
mbldefici
human
serum
without
rhmbl
hour
transduc
cell
cell
detach
use
trypl
wash
three
time
pb
rate
transduct
assay
flow
cytometri
comparison
baselin
valu
p
p
wt
refer
wild
type
mutant
refer
glycosyl
mutant
wnv
e
protein
hmbl
refer
human
mbl
mbl
bind
virus
figur
furthermor
mblenhanc
hivebov
gp
infect
significantli
diminish
deglycosyl
virion
use
pngase
f
endo
h
leav
expos
nacetylglucosamin
residu
polypeptid
chain
may
serv
ligand
mbl
figur
find
confirm
fact
mblmediat
enhanc
viral
infect
abrog
thermolysintr
hivebov
gp
virion
thermolysinconcentr
depend
manner
figur
mbl
also
significantli
reduc
capac
enhanc
ebov
infect
gp
lack
portion
glycosyl
mucinrich
region
figur
noteworthi
howev
infect
level
ebov
mutat
gp
higher
wildtyp
gp
pseudotyp
like
absenc
gp
mucinrich
region
expos
put
ebov
receptor
bind
region
facilit
infect
cell
hand
mbl
enhanc
infect
vsvg
pseudotyp
virion
indic
extent
mbl
select
find
rais
question
whether
mbl
crosslink
viru
put
cell
surfac
receptor
known
ebov
protect
host
immun
downregul
host
protein
includ
immun
regulatori
molecul
receptor
integrin
via
steric
occlus
refer
glycan
umbrella
effect
circumv
constraint
infect
propos
ebov
may
exploit
put
mbl
receptor
enter
cell
without
engag
ebovspecif
receptor
although
cognat
receptor
mbl
known
certainti
potenti
receptor
mbl
includ
complement
receptor
calreticulin
bind
protein
globular
domain
proven
andor
predict
nlink
glycopeptid
therefor
test
whether
reduct
nlink
glycoprotein
receptor
express
chemic
tunicamycin
genet
gnti
cell
approach
could
reduc
mblmediat
hivebov
gp
infect
tunicamycin
complet
inhibit
nlink
glycosyl
abrog
mblmediat
pseudotyp
ebov
infect
greater
extent
downstream
nglycantrim
agent
deoxynojirimycin
swainsonin
leav
residu
mannos
glcnac
residu
figur
similarli
nlink
glycosylationdefici
cell
resist
mblmediat
enhanc
figur
taken
togeth
result
show
mbl
interact
nlink
glycoprotein
traffick
via
er
golgi
apparatu
find
corrobor
fact
collagen
stalk
mbl
bind
calreticulin
put
receptor
lung
collectin
surfact
protein
also
bind
ligand
via
collagen
tail
mechan
ebov
attach
intern
studi
extens
ebov
attach
variou
put
attach
factor
cell
surfac
undergo
either
clathrincaveola
dynaminindepend
actinlipid
raftdepend
macropinocytosislik
endocytosi
clathrincaveolaedynamindepend
endocytosi
depend
type
target
cell
involv
virion
traffick
earli
late
endosom
undergo
proteolysi
acidifi
endocyt
vesicl
cathepsin
l
andor
b
remov
mucinlik
region
gp
lead
enhanc
viral
bind
infect
previou
studi
use
replicationcompet
infecti
ebov
ebov
virionlik
particl
pseudotyp
lentivirus
find
infect
assay
use
ebov
gp
pseudotyp
lentivirus
agre
saeed
et
al
use
wild
type
virus
extent
ebov
undergo
macropinocytosislik
endocytosi
figur
lipid
raftdepend
figur
dynaminindepend
figur
manner
addit
found
mbl
diminish
depend
actin
filament
microtubul
earli
endosom
acidif
infect
figur
f
figur
suggest
mbl
may
traffic
virus
via
noncanon
pathway
resembl
clathrincaveolindynaminactinindepend
microtubuledepend
endocyt
pathway
util
lymphocyt
choriomening
viru
lcmv
recombin
lcmvlassa
viru
gp
infecti
virion
detail
mechanist
studi
requir
confirm
find
determin
phenomenon
mbldepend
enhanc
applic
clinic
relev
target
test
human
monocytederiv
macrophag
cell
line
figur
primari
human
macrophag
figur
repres
type
cell
target
earli
cours
natur
ebov
infect
mbl
inde
enhanc
hivebov
gp
infect
type
cell
sought
identifi
cellular
surfac
receptor
mediat
mblenhanc
viral
infect
conduct
rnai
screen
use
least
uniqu
shrnaexpress
vector
per
gene
mitig
impact
differenti
effect
possibl
offtarget
effect
shrna
test
assay
compar
level
hivebov
gp
infect
knock
figur
reduc
infect
consist
known
role
mediat
viral
entri
use
techniqu
reveal
knock
three
shrna
construct
confirm
western
blot
figur
reduc
hivebov
gp
infect
variabl
extent
two
three
shrna
treatment
variabl
shrna
well
describ
notabl
knock
shrna
augment
presenc
mbl
significantli
greater
extent
effect
shrna
reduct
infect
suggest
mbl
play
supplementari
role
mediat
viral
entri
figur
tetramer
transmembran
surfac
protein
express
human
monocyt
varieti
cell
bind
globular
head
via
amino
terminu
high
affin
contain
three
potenti
nglycosyl
site
implic
innat
adapt
immun
viral
ligand
shown
activ
transloc
inhibit
rna
helicas
turn
inhibit
antivir
signal
downregul
type
interferon
given
induct
inhibit
ebov
replic
specul
ebovmbl
complex
activ
neg
regul
inhibit
viral
infect
therebi
enhanc
viral
prolifer
howev
clear
avoid
bind
circul
mbl
normal
physiolog
condit
one
hypothesi
mbl
undergo
conform
chang
upon
bind
viral
target
turn
could
expos
potenti
bind
site
mbl
collagen
stalk
engag
furthermor
show
knock
ctype
lectin
receptor
reduc
experiment
infect
ebov
figur
express
certain
macrophag
monocyt
dendrit
cell
target
ebov
earli
cours
infect
receptor
invok
previous
viral
pathogenesi
studi
requir
determin
specif
physic
andor
function
interact
ebov
mbl
determin
receptor
play
role
nativ
ebov
infect
final
investig
whether
mbl
enhanc
nativ
ebov
certain
glycosyl
viru
infect
low
complement
condit
rhmbl
inde
enhanc
infect
wild
typelik
ebov
west
nile
virionlik
particl
nativ
nipah
hendra
virus
respect
suggest
virus
adorn
nglycan
also
potenti
mbl
vari
extent
figur
expect
mblenhanc
ebov
infect
mitig
mannan
tunicamycin
figur
infect
wnv
glycosyl
mutant
enhanc
mbl
figur
plausibl
lifethreaten
glycosyl
virus
form
glycosyl
virion
old
world
measl
variola
virus
exert
pressur
evolut
mbl
genotyp
previous
appreci
support
hypothesi
mbl
enhanc
infect
caus
certain
glycosyl
virion
evid
individu
high
mbl
concentr
highproduc
mbl
haplotyp
experi
enhanc
infect
caus
glycosyl
intracellular
pathogen
leishmania
spp
mycobacterium
leprosum
tuberculosi
opportunist
organ
hivinfect
individu
tobin
et
al
identifi
mutat
zebrafish
human
leukotrien
hydrolas
gene
confer
heterozyg
advantag
mycobacterium
marinum
tuberculosi
respect
result
set
groundbreak
preced
understand
snp
singl
human
gene
dictat
dichotom
inflammatori
state
either
inadequ
excess
immun
respons
result
increas
sever
tb
mening
human
similarli
specul
certain
circumst
high
low
level
mbl
may
predispos
individu
certain
infecti
diseas
furthermor
hypothesi
high
level
mbl
may
deleteri
support
conceptu
recent
report
demonstr
role
mbl
mediat
immun
patholog
mous
model
ross
river
viru
rrv
arthriti
high
mbl
level
serum
synovi
fluid
human
rrv
correl
diseas
sever
mbl
also
implic
murin
model
pandem
influenza
avian
influenza
risk
factor
sever
diseas
upregul
inflammatori
respons
also
evid
inhibit
lectin
pathway
confer
consider
protect
noninfecti
disord
myocardi
gastrointestin
ischemiareperfus
injuri
therefor
possibl
evolutionari
select
mutant
mbl
allel
confer
protect
varieti
pathogen
andor
reduc
deleteri
effect
complementmedi
inflamm
exampl
preserv
heterozygoz
includ
sicklecel
trait
protect
malaria
despit
disadvantag
healthi
popul
also
persist
regulatori
mutat
duffi
antigen
chemokin
receptor
confer
resist
malaria
wide
variat
plasma
concentr
mbl
certain
complement
compon
occur
natur
variat
due
divers
genotyp
mbl
complement
compon
encod
copi
gene
well
complement
compon
partial
defici
one
common
immun
protein
defici
human
caus
complex
pattern
differ
gene
size
gene
number
nucleotid
polymorph
specif
homoexpress
delet
estim
occur
normal
caucasian
total
defici
occur
defici
finnish
popul
mean
protein
level
vari
gl
european
american
asian
indian
popul
howev
notabl
total
protein
level
span
rang
approxim
gl
higher
concentr
correl
larger
number
gene
copi
although
preval
homozyg
defici
caucasian
rare
approxim
partial
defici
estim
affect
western
european
addit
certain
infecti
diseas
may
modul
complement
level
eg
acut
malaria
pervas
ancient
infecti
diseas
caus
hypocomplementemia
furthermor
complement
may
reduc
vari
extent
certain
autoimmun
condit
drive
immun
complex
format
although
event
rel
rare
investig
hypothesi
rel
low
level
complement
may
permit
mbl
enhanc
viral
infect
perform
infect
assay
serial
dilut
serum
observ
serum
contain
higher
concentr
nativ
mbl
enhanc
hivebov
gp
infect
greatest
extent
serum
dilut
least
figur
show
critic
factor
serum
dilut
abrog
mbl
capac
enhanc
infect
complement
specif
figur
context
model
viral
infect
use
high
level
rhmbl
mgml
serum
ie
dilut
howev
high
concentr
rhmbl
consid
supraphysiolog
adjust
dilut
factor
serum
although
human
mbl
produc
primarili
liver
extrahepat
mbl
synthesi
found
gastrointestin
tract
middl
ear
fluid
nasopharyng
secret
possibl
express
differenti
induc
variou
compart
respons
differ
stimuli
similarli
extrahepat
complement
synthesi
regul
may
influenc
local
concentr
complement
furthermor
dysfunct
variant
may
attenu
capac
activ
complement
frequenc
defici
nonfunct
rang
differ
popul
highest
valu
african
specul
rel
mbl
excess
set
rel
low
level
defici
may
lead
mblmediat
enhanc
viral
infect
clinic
set
thu
propos
mbl
among
other
contribut
lattic
immun
molecul
repres
individu
innat
immun
haplotyp
individu
effector
may
necessarili
dictat
outcom
infect
aggreg
immunolog
state
may
influenc
person
suscept
resist
infect
precis
mechan
mbl
enhanc
infect
glycosyl
virion
known
specul
mbl
concentr
viru
target
cell
surfac
certain
circumst
mbl
exce
complement
level
facilit
crosslink
ebov
cognat
receptor
attach
factor
mgl
may
facilit
subsequ
membran
fusion
intern
macropinocytosi
figur
studi
potenti
limit
fact
use
pseudotyp
virus
mechanist
experi
composit
viral
envelop
depend
part
cell
type
virus
produc
therefor
observ
interact
hivebovgp
host
attach
factor
may
artifici
howev
show
similar
phenomenon
wild
typelik
ebov
glycosyl
virus
furthermor
shown
gp
ebolavirus
ebov
rel
contain
highmannos
hybrid
nlink
glycan
independ
cell
line
use
viral
propag
anoth
limit
studi
lack
direct
evid
human
complement
compon
specif
suffici
low
vivo
certain
circumst
permit
mbl
mediat
enhanc
uptak
glycosyl
virus
use
media
supplement
human
serum
half
concentr
fetal
calf
fetal
bovin
serum
typic
use
ebov
infect
assay
given
gene
copi
number
variat
may
lead
proportion
reduct
circul
specul
experiment
ratio
mbl
use
studi
physiolog
plausibl
recent
clinic
studi
kainulainen
et
al
provid
preliminari
data
consist
hypothesi
synergi
defici
mbl
excess
may
predispos
children
adolesc
certain
infect
n
finnish
patient
recurr
respiratori
infect
n
healthi
control
p
defici
unexpectedli
patient
defici
mbl
concentr
mgml
mean
human
mbl
serum
concentr
notabl
onethird
high
mbl
level
mg
ml
clinic
studi
requir
investig
signific
appar
associ
conclus
studi
reveal
mbl
complex
role
infect
caus
ebov
glycosyl
virus
mbl
key
innat
immun
molecul
seemingli
paradox
function
depend
level
complement
demonstr
first
time
phenomenon
mbldepend
enhanc
infect
caus
glycosyl
virion
low
complement
condit
discov
role
ebov
pathogenesi
postul
individu
innat
immun
haplotyp
defin
interact
genotyp
mbl
possibl
other
find
highlight
possibl
administr
supraphysiolog
dose
mbl
product
blood
product
high
mbl
concentr
individu
set
infecti
diseas
rel
hypocomplementemia
may
deleteri
certain
condit
hand
intrigu
consid
mbl
might
use
adjuv
enhanc
deliveri
glycosyl
vaccin
epitop
effector
immun
system
final
find
suggest
pressur
infecti
diseas
may
driven
part
evolutionari
select
mbl
mutant
haplotyp
encod
low
intermedi
mbl
serum
level
major
human
figur
rhmbl
enhanc
hivebov
gp
infect
calciumdepend
manner
preincub
hivebovgp
virionlik
particl
rhmbl
mbldefici
serum
veronalbuff
salin
without
calcium
supplement
mm
cacl
versu
mm
cacl
mgml
rhmbl
respect
pairwis
comparison
mgml
rhmbl
experi
perform
twice
quadrupl
ep
figur
mbl
activ
sera
panel
healthi
subject
measur
nativ
mbl
concentr
mannanbind
activ
mbl
cleavag
activ
sera
healthi
adult
volunt
caucasian
asian
hispan
africanamerican
ancestri
femal
n
sampl
log
rang
mbl
concentr
ngml
strongli
correl
concord
mbl
cleavag
valu
uml
r
sampl
includ
three
individu
homozyg
null
allel
b
c
detect
mbl
lower
limit
detect
mbl
concentr
ngml
cleavag
activ
uml
expect
significantli
individu
wildtyp
haplotyp
aa
mbl
concentr
ngml
vs
mbl
cleavag
activ
uml
vs
compar
oo
oa
haplotyp
refer
b
c
allel
ep
figur
endoglycosidas
cleav
nlink
glycan
hivebov
gp
preincub
hiveboz
gp
virionlik
particl
pgml
pngase
f
endo
h
uml
dilut
dmem
dmem
alon
hour
virus
underw
gel
electrophoresi
product
transfer
onto
nitrocellulos
membran
detect
incub
biotinyl
hippeastrum
hybrid
lectin
follow
streptavidinhorseradish
peroxidas
hrp
membran
incub
immobilon
western
chemiluminesc
ap
substrat
expos
autoradiographi
film
highmannos
moieti
preserv
untreat
viru
confirm
pngase
f
endo
h
effect
cleav
highmannos
residu
gp
hivebov
virionlik
particl
ep
figur
thermolysin
treatment
hivebov
gp
abrog
enhanc
infect
rhmbl
thermolysinconcentr
depend
manner
preincub
hivebov
gp
virionlik
particl
pg
ml
without
thermolysin
mg
ml
buffer
mm
hepe
mm
me
mm
nacl
mm
cacl
shake
minut
reaction
termin
mm
edta
cell
infect
thermolysintr
virionlik
particl
mix
mbl
carbohydr
recognit
domain
crd
bind
highli
glycosyl
mucinrich
region
ebov
gp
mblvirion
complex
present
cell
surfac
mbl
bind
cognat
cellular
receptor
calreticulin
via
mbl
collagen
stalk
manner
mbl
concentr
viru
cell
surfac
may
facilit
crosslink
ebov
cognat
receptor
attach
factor
may
facilit
subsequ
membran
fusion
intern
rel
larg
size
ebov
particl
nm
amen
bulk
fluidphas
uptak
pathway
macropinocytosi
canon
pathway
ebov
entri
data
indic
mbl
also
mediat
intern
viru
via
macropinocytosi
suggest
mblmediat
uptak
preferenti
util
microtubul
compar
canon
ebov
pathway
depend
microtubul
actin
mbldefici
ngml
human
serum
alon
supplement
mgml
rhmbl
describ
materi
method
luciferas
valu
adjust
cell
viabil
use
alamarblu
resazurin
reduct
assay
shown
averag
adjust
luciferas
result
two
experi
four
replic
maxim
reduct
viral
infect
presenc
rhmbl
wherea
inhibit
infect
absenc
mbl
ep
figur
mblmediat
macropinocytosi
hivebov
gp
may
bypass
earli
endosom
dynamin
independ
preincub
cell
amilorid
hydrochlorid
inhibitor
na
h
exchang
activ
b
bafilomycin
specif
potent
inhibitor
vacuolar
h
atpas
earli
endosom
c
monensin
inhibitor
endosom
acidif
receptor
recycl
dynasor
potent
specif
dynamin
inhibitor
involv
clathrinand
caveolinmedi
endocytosi
mbldefici
serum
absenc
presenc
rhmbl
hour
infect
cell
hivebovgp
virionlik
particl
pg
ml
percentag
infect
cell
rel
dmso
control
methanol
control
use
monensin
luciferas
valu
adjust
cell
viabil
use
alamarblu
resazurin
reduct
assay
signific
differ
shown
experi
perform
twice
quadrupl
ep
figur
shrna
knockdown
cathepsinl
mgl
perform
rna
interfer
vector
encod
shrna
target
b
mgl
describ
figur
luciferas
valu
adjust
cell
viabil
percentag
chang
infect
normal
empti
control
vector
ep
figur
rhmbl
target
nlink
glycan
surfac
wild
typelik
ebov
cell
preincub
mbldefici
serum
without
mbl
supplement
media
mannan
mgml
hour
incub
wild
typelik
ebovegfp
mayinga
variant
prepar
hour
final
infect
cell
virion
multipl
infect
b
preincub
cell
vari
concentr
tunicamycin
ii
wild
typelik
ebovegfp
mbldefici
serum
without
rhmbl
supplement
hour
infect
cell
viru
multipl
infect
fluoresc
assay
hour
infect
signific
differ
shown
experi
perform
triplic
ep
